Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors

Abstract. Doxorubicin is a commonly used chemotherapeutic employed to treat multiple human cancers, including numerous sarcomas and carcinomas. Furthermore, doxorubicin possesses strong fluorescent properties that make it an ideal reagent for modeling drug delivery by examining its distribution in cells and tissues. However, while doxorubicin fluorescence and lifetime have been imaged in live tissue, its behavior in archival samples that frequently result from drug and treatment studies in human and animal patients, and murine models of human cancer, has to date been largely unexplored. Here, we demonstrate imaging of doxorubicin intensity and lifetimes in archival formalin-fixed paraffin-embedded sections from mouse models of human cancer with multiphoton excitation and multiphoton fluorescence lifetime imaging microscopy (FLIM). Multiphoton excitation imaging reveals robust doxorubicin emission in tissue sections and captures spatial heterogeneity in cells and tissues. However, quantifying the amount of doxorubicin signal in distinct cell compartments, particularly the nucleus, often remains challenging due to strong signals in multiple compartments. The addition of FLIM analysis to display the spatial distribution of excited state lifetimes clearly distinguishes between signals in distinct compartments such as the cell nuclei versus cytoplasm and allows for quantification of doxorubicin signal in each compartment. Furthermore, we observed a shift in lifetime values in the nuclei of transformed cells versus nontransformed cells, suggesting a possible diagnostic role for doxorubicin lifetime imaging to distinguish normal versus transformed cells. Thus, data here demonstrate that multiphoton FLIM is a highly sensitive platform for imaging doxorubicin distribution in normal and diseased archival tissues.

[1]  N. Ramanujam,et al.  Metabolic mapping of MCF10A human breast cells via multiphoton fluorescence lifetime imaging of the coenzyme NADH. , 2005, Cancer research.

[2]  N. Bachur,et al.  Cytofluorescence localization of adriamycin and daunorubicin. , 1974, Cancer Research.

[3]  L. Zelek,et al.  Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review , 2013, Orphanet Journal of Rare Diseases.

[4]  Feng-Chun Yang,et al.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression. , 2012, Annual review of pathology.

[5]  Neil O Carragher,et al.  Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer. , 2013, Cancer research.

[6]  Paolo P. Provenzano,et al.  Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer , 2013, British Journal of Cancer.

[7]  H Szmacinski,et al.  Fluorescence lifetime imaging. , 1992, Analytical biochemistry.

[8]  Triantafyllos Stylianopoulos,et al.  Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. , 2011, Annual review of chemical and biomolecular engineering.

[9]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[10]  S. Henikoff,et al.  Doxorubicin, DNA torsion, and chromatin dynamics. , 2014, Biochimica et biophysica acta.

[11]  D. Largaespada,et al.  Conditional Inactivation of Pten with EGFR Overexpression in Schwann Cells Models Sporadic MPNST , 2012, Sarcoma.

[12]  R. Jain,et al.  Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors , 2011, Proceedings of the National Academy of Sciences.

[13]  J. Goedhart,et al.  Combination of a spinning disc confocal unit with frequency‐domain fluorescence lifetime imaging microscopy , 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[14]  Rakesh K. Jain,et al.  Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels , 2013, Nature Communications.

[15]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[16]  S. Kaufmann,et al.  How does doxorubicin work? , 2012, eLife.

[17]  D. Kerr,et al.  Cytotoxic drug penetration studies in multicellular tumour spheroids. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  Jae-Hyun Park,et al.  Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. , 2012, Cancer cell.

[19]  R. Day,et al.  Investigating protein-protein interactions in living cells using fluorescence lifetime imaging microscopy , 2011, Nature Protocols.

[20]  B. Denard,et al.  Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1 , 2012, eLife.

[21]  C. Rueden,et al.  Bmc Medicine Collagen Density Promotes Mammary Tumor Initiation and Progression , 2022 .

[22]  Fatemeh Atyabi,et al.  Fluorescence properties of several chemotherapy drugs: doxorubicin, paclitaxel and bleomycin. , 2016, Biomedical optics express.

[23]  A. Bodley,et al.  DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. , 1989, Cancer research.

[24]  R. Medema,et al.  Intravital FRET Imaging of Tumor Cell Viability and Mitosis during Chemotherapy , 2013, PloS one.

[25]  Derek S. Chan,et al.  Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer , 2012, Gut.

[26]  I. Tannock,et al.  Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib , 2012, BMC Cancer.

[27]  D. Kerr,et al.  Aspects of cytotoxic drug penetration, with particular reference to anthracyclines , 2004, Cancer Chemotherapy and Pharmacology.

[28]  P. Friedl,et al.  Fluorescence lifetime microscopy of tumor cell invasion, drug delivery, and cytotoxicity. , 2012, Methods in enzymology.

[29]  Paolo P. Provenzano,et al.  Shining new light on 3D cell motility and the metastatic process. , 2009, Trends in cell biology.

[30]  R. Durand Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage? , 2008, Cancer Chemotherapy and Pharmacology.

[31]  M. van Glabbeke,et al.  First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  C. Mou,et al.  Probing the Dynamics of Doxorubicin-DNA Intercalation during the Initial Activation of Apoptosis by Fluorescence Lifetime Imaging Microscopy (FLIM) , 2012, PloS one.

[33]  K. Ulbrich,et al.  Spectral analysis of doxorubicin accumulation and the indirect quantification of its DNA intercalation. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[34]  D. Gewirtz,et al.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. , 1999, Biochemical pharmacology.

[35]  Jens Eickhoff,et al.  In vivo multiphoton fluorescence lifetime imaging of protein-bound and free nicotinamide adenine dinucleotide in normal and precancerous epithelia. , 2007, Journal of biomedical optics.

[36]  Meiyuan Xing,et al.  Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials , 2015, PloS one.

[37]  Yazhou Wang,et al.  Transport barriers and strategies of antitumor nanocarriers delivery system. , 2013, Journal of biomedical materials research. Part A.

[38]  Kevin W. Eliceiri,et al.  Multiphoton microscopy and fluorescence lifetime imaging microscopy (FLIM) to monitor metastasis and the tumor microenvironment , 2008, Clinical & Experimental Metastasis.

[39]  R. Pazo-Cid,et al.  Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review , 2013, Journal of drug delivery.

[40]  R. Rosenfeld,et al.  Deciphering the fluorescence signature of daunomycin and doxorubicin. , 1998, Biophysical chemistry.

[41]  Michael A Babcock,et al.  Neurofibromatosis Type 1 Revisited , 2009, Pediatrics.

[42]  I. Gryczynski,et al.  Fluorescence properties of doxorubicin in PBS buffer and PVA films. , 2017, Journal of photochemistry and photobiology. B, Biology.

[43]  M. Baker,et al.  Multiphoton fluorescence lifetime imaging microscopy reveals free-to-bound NADH ratio changes associated with metabolic inhibition. , 2014, Journal of biomedical optics.

[44]  S. Rabkin,et al.  The effect of doxorubicin (adriamycin) on cytoplasmic microtubule system in cardiac cells. , 1987, Journal of molecular and cellular cardiology.

[45]  E. V. van Munster,et al.  Fluorescence lifetime imaging microscopy (FLIM). , 2005, Advances in biochemical engineering/biotechnology.

[46]  Lothar Lilge,et al.  The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.

[47]  J. Lankelma,et al.  Doxorubicin gradients in human breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  H. Schneckenburger,et al.  Cholesterol Dependent Uptake and Interaction of Doxorubicin in MCF-7 Breast Cancer Cells , 2013, International journal of molecular sciences.

[49]  C. Kaminski,et al.  Fluorescence intensity and lifetime imaging of free and micellar-encapsulated doxorubicin in living cells. , 2008, Nanomedicine : nanotechnology, biology, and medicine.

[50]  Ivanov,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[51]  D. Largaespada,et al.  PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors. , 2012, Cancer research.

[52]  M. Parsons,et al.  Integrin α3β1–CD151 complex regulates dimerization of ErbB2 via RhoA , 2014, Oncogene.

[53]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[54]  Tina Hernandez-Boussard,et al.  Doxorubicin pathways: pharmacodynamics and adverse effects , 2011, Pharmacogenetics and genomics.

[55]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[56]  Paolo P. Provenzano,et al.  Nonlinear optical imaging and spectral-lifetime computational analysis of endogenous and exogenous fluorophores in breast cancer. , 2008, Journal of biomedical optics.

[57]  Walter J. Riker A Review of J , 2010 .

[58]  Paolo P. Provenzano,et al.  Anisotropic forces from spatially constrained focal adhesions mediate contact guidance directed cell migration , 2017, Nature Communications.

[59]  S. Monti,et al.  Unravelling molecular mechanisms in the fluorescence spectra of doxorubicin in aqueous solution by femtosecond fluorescence spectroscopy. , 2013, Physical chemistry chemical physics : PCCP.